Search results
Showing 1261 to 1275 of 1433 results for primary care
This guideline covers how to improve the physical environment to encourage and support physical activity. The aim is to increase the general population’s physical activity levels.
Guadecitabine for untreated acute myeloid leukaemia [ID1411]
Discontinued Reference number: GID-TA10325
TactiCath Quartz catheter for percutaneous radiofrequency ablation in atrial fibrillation (MIB60)
NICE has developed a medtech innovation briefing (MIB) on the TactiCath Quartz catheter for percutaneous radiofrequency ablation in atrial fibrillation
Digital technologies to support smoking cessation in secondary care patients: early value assessment
In development Reference number: GID-HTE10061 Expected publication date: TBC
Emapalumab for treating primary haemophagocytic lymphohistiocytosis (ID1438)
Discontinued Reference number: GID-TA10527
Xpert GBS test for the intrapartum detection of group B streptococcus (MIB28)
NICE has developed a medtech innovation briefing (MIB) on Xpert GBS test for the intrapartum detection of group B streptococcus
NICE has developed a medtech innovation briefing (MIB) on artificial intelligence in mammography .
Evidence-based recommendations on nivolumab (Opdivo) with fluoropyrimidine- and platinum-based chemotherapy for untreated unresectable advanced, recurrent, or metastatic oesophageal squamous cell carcinoma in adults.
Evidence-based recommendations on pembrolizumab (Keytruda) for untreated metastatic or unresectable recurrent head and neck squamous cell carcinoma (HNSCC) in adults whose tumours express PD L1 with a combined positive score (CPS) of 1 or more.
Evidence-based recommendations on pembrolizumab (Keytruda) for relapsed or refractory classical Hodgkin lymphoma in people aged 3 and older who have had a stem cell transplant or at least 2 previous therapies.
Palforzia for treating peanut allergy in children and young people (TA769)
Evidence-based recommendations on Palforzia for treating peanut allergy in children and young people.
This guide describes the methods and processes that NICE follows when producing HealthTech guidance. For interventional procedures, this guide covers NICE processes. Methods for interventional procedures guidance are in the NICE's interventional procedures programme manual. The NICE HealthTech programme combines the former NICE Diagnostics Assessment programme, Interventional Procedures programme and Medical Technologies Evaluation programme
Ravulizumab for treating atypical haemolytic uraemic syndrome (TA710)
Evidence-based recommendations on ravulizumab (Ultomiris) for treating atypical haemolytic uraemic syndrome in people weighing 10 kg or more.
Lenalidomide plus dexamethasone for previously untreated multiple myeloma (TA587)
Evidence-based recommendations on lenalidomide (Revlimid) plus dexamethasone for previously untreated multiple myeloma in adults.
Evidence-based recommendations on glofitamab (Columvi) for treating relapsed or refractory diffuse large B-cell lymphoma in adults after 2 or more systemic treatments.